Travere Therapeutics, Inc. announced that its chief medical officer, Noah Rosenberg, M.D., would be transitioning to an executive advisor role effective January 1, 2022.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
6.19 USD | -2.37% | +2.39% | -30.98% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-30.98% | 483M | |
+12.19% | 116B | |
+12.64% | 106B | |
-9.39% | 23.89B | |
-1.69% | 21.58B | |
-10.60% | 18.96B | |
-41.25% | 16.96B | |
-15.28% | 16.33B | |
+6.27% | 14.14B | |
+29.81% | 12.02B |
- Stock Market
- Equities
- TVTX Stock
- News Travere Therapeutics, Inc.
- Travere Therapeutics, Inc. Announces Executive Changes